Tadocizumab

Names

[ CAS No. ]:
339086-80-5

[ Name ]:
Tadocizumab

Biological Activity

[Description]:

Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research[1][2].

[Related Catalog]:

Research Areas >> Cardiovascular Disease
Signaling Pathways >> Cytoskeleton >> Integrin

[Target]

GPIIb/IIIa


[In Vitro]

Tadocizumab (YM-337) 显着抑制体外 ADP 诱导的血小板聚集，并完全抑制花生四烯酸诱导的血小板聚集[1]。 Tadocizumab (YM-337) 抑制人血小板粘附到 von Willebrand 因子、纤维蛋白原、纤连蛋白和内皮下基质[2]。

[In Vivo]

Tadocizumab (YM-337; C4G1) 剂量依赖性地抑制离体血小板聚集，在恒河猴中以高于 0.25 mg/kg 静脉注射或 1.5 μg/kg/min 输注的剂量完全抑制[1]。 在松鼠猴的光化学诱导血栓形成模型中，Tadocizumab (YM-337；C4G1) 以 1 mg/kg 的剂量静脉注射，然后以 6 μg/kg/min 的速度输注 60 分钟，可预防实验猴子的闭塞性血栓形成[1]。

[References]

[1]. S Kaku, et al. Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys. Thromb Haemost. 1996 Apr;75(4):679-84.  

[2]. Ken-ichi Suzuki, et al. Comparative studies of a humanized anti-glycoprotein IIb/IIIa monoclonal antibody, YM337, and abciximab on in vitro antiplatelet effect and binding properties. Biol Pharm Bull. 2002 Aug;25(8):1006-12.  

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.